# Clene (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome

* Clene revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado
* The only current FDA-approved drug for Rett Syndrome is trofinetide, approved in 2023
* CNM-Au8 treatment showed improvements in mitochondrial respiration deficits in Rett patient-derived astrocytes

 Clene (NASDAQ: CLNN), along with its subsidiary Clene Nanomedicine Inc., a biopharmaceutical company specializing in mitochondrial health to address neurological diseases like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment. The data was presented by Dr. Karen Ho, Clene’s Vice President of Translational Medicine, at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado. The presentation, titled “CNM-Au8, a Candidate First-in-Class Nanotherapeutic for Treatment of Rett Syndrome,” highlighted CNM-Au8’s potential (https://ibn.fm/NAtz7).

 Rett Syndrome is a severe and rare pediatric neurological disorder caused by mutations in the MECP2 gene on the X chromosome. It predominantly affects females, occurring in about 1 in 10,000 live female births. Children with MECP2 mutations develop normally for the first six months of life but then…

 Read More>>

 NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

 Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

 The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

 Corporate Communications

 IBN (InvestorBrandNetwork)Los Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ult-prem/clene-nasdaq-clnn-presents-promising-preliminary-data-on-cnm-au8r-for-rett-syndrome/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/clene-unveils-promising-data-on-cnm-au8-for-rett-syndrome-treatment/45db50be4e7f409e7819f2a3a08077c9) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1f2qwe4/clene_unveils_promising_data_on_cnmau8_for_rett/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/248/27/beanf5VH.webp)